Details for Patent: 8,829,195
✉ Email this page to a colleague
Which drugs does patent 8,829,195 protect, and when does it expire?
Patent 8,829,195 protects SCEMBLIX and is included in one NDA.
This patent has seventy-two patent family members in forty-nine countries.
Summary for Patent: 8,829,195
| Title: | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| Abstract: | The present invention relates to compounds of formula (I): ##STR00001## in which Y, Y.sub.1, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. |
| Inventor(s): | Dodd; Stephanie Kay (Ayer, MA), Furet; Pascal (Thann, FR), Grotzfeld; Robert Martin (Ettingen, CH), Jahnke; Wolfgang (Lorrach, DE), Jones; Darryl Brynley (Basel, CH), Manley; Paul William (Arlesheim, CH), Marzinzik; Andreas (Weil, DE), Pelle; Xavier Francois Andre (Kembs, FR), Salem; Bahaa (Basel, CH), Schoepfer; Joseph (Riehen, CH) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 13/892,769 |
|
Patent Claim Types: see list of patent claims | Use; Compound; |
Drugs Protected by US Patent 8,829,195
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-001 | Oct 29, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) | ⤷ Sign Up | |||
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-002 | Oct 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) | ⤷ Sign Up | |||
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-003 | Apr 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,829,195
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2861579 | ⤷ Sign Up | 301201 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2861579 | ⤷ Sign Up | CR 2022 00046 | Denmark | ⤷ Sign Up |
| European Patent Office | 2861579 | ⤷ Sign Up | PA2022523 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2861579 | ⤷ Sign Up | 2022C/548 | Belgium | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
